Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

A.L. Noordhof, R.A.M. Damhuis, L.E.L. Hendriks, A.J. de Langen, W. Timens, B.J.W. Venmans, W.H. van Geffen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)163-169
Number of pages7
JournalLung Cancer
Volume155
DOIs
Publication statusPublished - 1 May 2021

Keywords

  • Non-small cell lung cancer
  • Kirsten rat sarcoma
  • Mono-immunotherapy
  • PREDICTIVE-VALUE
  • CANCER
  • EFFICACY
  • INHIBITORS
  • DOCETAXEL
  • SURVIVAL
  • THERAPY

Cite this